Investor Presentaiton
Top-tier talent
Differentiated process
Scalable platform
Successful history of investing in development-stage therapies
Robust development-stage portfolio
Invested $8bn in development-stage
therapies since 2012
☐
Require strong proof of concept data
Broad landscape of opportunities
Not constrained by therapeutic area
Target returns in the teens
•
10 development-stage therapies
currently in portfolio
History of identifying therapies with
unmet and underserved patient needs
Development-stage investments
Royalty Pharma approval success rate (2)
(by primary disease area(1))
Hypertrophic
cardiomyopathy
Multiple sclerosis
Solid tumors
Myelofibrosis
Rheumatoid
arthritis
Alzheimer's
disease
Depression
Paroxysmal
nocturnal
hemoglobinuria
Spinal muscle
atrophy
Migraine
Leukemia
Cystic fibrosis
Diabetes
Breast
cancer
Heart failure
Asthma
Inflammatory
disease
95%
79%
By number
of investments
By value
of investments
1.
ROYALTY PHARMA 2.
Split reflects the number of development-stage royalty acquisitions by primary disease area from 2012 through Q1 2022.
Approval success rate defined as any development-stage royalty acquisition that has received a regulatory decision on approval. Therapies not approved include investments in
vosaroxin, palbociclib and Merck KGaA's anti-IL17 nanobody M1095.
89
63View entire presentation